Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
First GLP-1 pill of its kind with flexible dosing Can be taken at any time of day No fasting or timing requirements Removes one of the biggest barriers vs injectable therapies Clinical impact (ATTain-1 trial): ~27 lbs average weight loss at highest dose ~12.4% body weight reduction Significant improvements in cardiometabolic markers (cholesterol, blood pressure, waist circumference) Weve seen explosive growth in GLP-1 injectables but: Many patients delay or avoid treatment due to injections Adherence can be a challenge Access and convenience remain barriers A simple oral option could expand the market significantly and reach patients earlier in their journey
That gave so-called compounders, which make copycat versions of Wegovy that may be tweaked slightly to personalize them, more of a foothold
Why this helps Creates a calmer next step for people comparing online care
While AD is at the forefront of research into the use of insulin in neurodegenerative disease, there is increasing attention being paid to the role of insulin signaling in PD
Insurance approvals for brand-name GLP-1s sometimes take several weeks
Laboratory tests may be repeated every six to twelve months as needed to evaluate blood sugar, cholesterol, liver function, kidney function, and thyroid levels
